NephroWorldCup 2022: Metformin or SGLT2i in CKD patients with Diabetes

NephroWorldCup 2022: Metformin or SGLT2i in CKD patients with Diabetes

Slick tricks with SGLT-2 inibitors and Metformin Magic!Подробнее

Slick tricks with SGLT-2 inibitors and Metformin Magic!

The consideration in using SGLT2 inhibitors in patients with CKDПодробнее

The consideration in using SGLT2 inhibitors in patients with CKD

CWMGR: The Expanding Multiverse of SGLTi In & Beyond DiabetesПодробнее

CWMGR: The Expanding Multiverse of SGLTi In & Beyond Diabetes

NephroWorldCup: Kidney benefits of GLP1RAПодробнее

NephroWorldCup: Kidney benefits of GLP1RA

Role of SGLT2 Inhibitors in CKDПодробнее

Role of SGLT2 Inhibitors in CKD

Prof. Wael Farag -Initial Therapy for Type II Diabetes SGLT2 VS Metformin.Подробнее

Prof. Wael Farag -Initial Therapy for Type II Diabetes SGLT2 VS Metformin.

Metformin vs Sulfonylurea in Patients With Type 2 Diabetes & CKDПодробнее

Metformin vs Sulfonylurea in Patients With Type 2 Diabetes & CKD

De Fronzo and SGLT2Подробнее

De Fronzo and SGLT2

Metformin Discontinuation and Clinical Outcomes in Advanced Chronic Kidney Disease and DiabetesПодробнее

Metformin Discontinuation and Clinical Outcomes in Advanced Chronic Kidney Disease and Diabetes

Beyond Metformin: Diabetes drugs as anti-aging targets | Dr. Nir BarzilaiПодробнее

Beyond Metformin: Diabetes drugs as anti-aging targets | Dr. Nir Barzilai

Treatment of type 2 diabetes and renal impairment - Video abstract 82008Подробнее

Treatment of type 2 diabetes and renal impairment - Video abstract 82008

Impact of metformin on outcomes for metastatic renal cell carcinomaПодробнее

Impact of metformin on outcomes for metastatic renal cell carcinoma

Improving Renal Outcomes With Glucose-Lowering Therapy in the Individualized Management of T2DMПодробнее

Improving Renal Outcomes With Glucose-Lowering Therapy in the Individualized Management of T2DM

Professor Alice Cheng - SGLT inhibitors - are there no therapeutic limitsПодробнее

Professor Alice Cheng - SGLT inhibitors - are there no therapeutic limits

Assimilating the Evidence in T2DM: Cardiovascular and Renal Outcomes With SGLT2 InhibitorsПодробнее

Assimilating the Evidence in T2DM: Cardiovascular and Renal Outcomes With SGLT2 Inhibitors

Nephrology Grand Rounds: SGLT2 InhibitorsПодробнее

Nephrology Grand Rounds: SGLT2 Inhibitors

Management of Diabetes and Hyperglycemia in CKD/ESRD PatientsПодробнее

Management of Diabetes and Hyperglycemia in CKD/ESRD Patients

Safety evaluation of empagliflozin for patients with type 2 diabetes and chronic kidney diseaseПодробнее

Safety evaluation of empagliflozin for patients with type 2 diabetes and chronic kidney disease